Eli Lilly & (LLY) Stock
Major pharmaceutical group with diabetes and obesity medicines. Here's the price, business snapshot, and what's worth knowing about Eli Lilly & in September 2026.
Eli Lilly and Company (LLY) is a major US pharmaceutical group with a broad portfolio spanning diabetes, oncology, immunology and neuroscience. With a market capitalisation around $756.8bn, Lilly is known for strong commercial medicines such as GLP-1 and dual-agonist therapies that have driven recent sales growth, alongside a diversified R&D pipeline. Investors should know Lilly combines steady cash-generating marketed products with growth from newer launches and late‑stage candidates, but faces typical sector risks: regulatory review, patent expiries, pricing scrutiny and competition. Financials can be resilient but are sensitive to trial outcomes and reimbursement decisions. As general information, this summary is educational not personal financial advice — returns are not guaranteed and values can fall as well as rise. Prospective investors should consider their objectives, time horizon and risk tolerance, and may wish to consult an authorised financial adviser before investing.
Why It’s Moving
Lilly stays in focus as deal activity and GLP-1 demand keep the growth story alive.
- Lilly is drawing attention after agreeing to acquire Merida Biosciences, extending its aggressive deal-making strategy and signaling management still sees room to expand its drug pipeline beyond the current obesity and diabetes franchise.
- Investors are also weighing fresh demand signals for GLP-1 therapies, including reports that prescriptions among younger patients are rising sharply, which reinforces the long runway for the category but also keeps pricing, access, and scrutiny in focus.
- The stock remains supported by ongoing analyst optimism around incretin growth, with recent commentary framing Lilly as one of the clearest beneficiaries of continued obesity-drug adoption and international launch momentum.
Lilly stays in focus as deal activity and GLP-1 demand keep the growth story alive.
- Lilly is drawing attention after agreeing to acquire Merida Biosciences, extending its aggressive deal-making strategy and signaling management still sees room to expand its drug pipeline beyond the current obesity and diabetes franchise.
- Investors are also weighing fresh demand signals for GLP-1 therapies, including reports that prescriptions among younger patients are rising sharply, which reinforces the long runway for the category but also keeps pricing, access, and scrutiny in focus.
- The stock remains supported by ongoing analyst optimism around incretin growth, with recent commentary framing Lilly as one of the clearest beneficiaries of continued obesity-drug adoption and international launch momentum.
Sixth Month Growth Performance
When is the next earnings date for Eli Lilly & Co (LLY)?
Eli Lilly’s next earnings date is expected to be October 29, 2026, before the market opens. The report will cover Q3 2026 results. This timing matches the company’s typical late-October third-quarter reporting pattern.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Eli Lilly's stock, expecting its price to rise in the future.
Financial Health
Eli Lilly is achieving strong revenue and profits, showcasing robust cash flow and margins.
Dividend
Eli Lilly's dividend yield of 0.58% is low, indicating modest returns. If you invested $1000, you would be paid $6.46 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Pipeline-led growth
Late-stage candidates and recent product roll-outs can boost revenue, though outcomes and timelines are uncertain and can affect share performance.
Global commercial reach
A wide geographic footprint helps diversify sales, but reimbursement policies and pricing pressure vary by market and may impact returns.
R&D and innovation
Heavy R&D investment fuels long-term potential, while the opposite side of the coin is the cost and risk of trials and regulatory review.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
